Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist

Enrolled subjects will be in one of two groups, they will apply a topical serum (AGE Serum) to the full face and neck twice daily for 12 weeks. Subject follow-up visits will occur at Week 6 and Week 12. Subjects will complete assessments and participate in and standardized 2D and 3D (Visia) digital photography.

Inclusion criteria

• Post-menopausal women (25 on HRT, 25 non HRT all must be post-menopausal)
• Presence of mild to moderate signs of facial aging (e.g., fine lines, laxity, dull texture) based on modified Griffith scale.
• Adult women aged 45-65 years.
• Fitzpatrick skin types I-VI.
• Current treatment with a stable dose of any GLP-1 agonist medication, including Ozempic, Rybelsus, or Wegovy for at least the last 3 months
• Must be willing to sign a photography release and ICF,and complete the entire course of the study.
• Subjects in good general health based on the investigator's judgment and medical history.

Exclusion criteria

• Non post-menopausal state.
• Any uncontrolled systemic disease.
• History of autoimmune connective tissue disease.
• Current use of immunosuppressive medication.
• Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
• Active dermatitis or active infection in the proposed treatment area.
• Mesotherapy; dermal fillers, biostimulator injectables; radiofrequency device treatments; microfocused ultrasound device treatments; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery during the 12-month period before study treatment.
• Microneedling treatments of the face and neck during the 1 month period before study treatment
• Laser and light based device treatments of the face and neck. Ablative lasers 6-month period before study treatment, and 3-month period for non-ablative lasers.
• Any neurotoxin injection to the face or neck during the 6-month period before study treatment
• Subjects using any treatment skincare products must discontinue use of these products 2 weeks before the start of participating in this clinical study and for the duration of the study.
• Subjects with scarring in the treatment areas, which in the opinion of the investigator could impact results. Subjects with a history of keloids will be excluded.
• Subjects who spray tanned or used sunless tanners in the treatment areas 1-month prior to study treatment.
• History of connective tissue disease (e.g., lupus, scleroderma), history of Bell's Palsy, history of smoking.
• Inability to ambulate following the procedure.
• Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study.
• Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.